Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Vibrio cholerae live attenuated may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Vaxchora is an oral vaccine against cholera that stimulates the immunological defence in the gut. The vaccine is used for protection from cholera in adults and children aged 2 years and older. The vaccine must be taken at least 10 days before travelling to a cholera-affected area. How Vaxchora works Vaxchora prepares the immune system (the body's defences) to defend itself against cholera. When a person takes the vaccine, the immune system makes proteins called antibodies against the cholera bacterium and its toxin (harmful substance) that causes diarrhoea. In this way the immune system is ready to fight cholera bacteria if the person comes into contact with it.
2.
e Vaxchora
Do not take Vaxchora: – if you are allergic to any of the ingredients in this medicine (listed in section 6). – if you have a weakened immune system, for example, if you were born with a weakened immune system or if you are having treatments such as high-dose corticosteroid treatment, cancer medicines or radiotherapy that can weaken the immune system. Warnings and precautions Talk to your doctor, pharmacist, or nurse before taking Vaxchora. Contact a doctor immediately if you get the following serious side effects (see also Section 4): • serious allergic reactions causing swelling of the face or throat, hives, itchy rash, breathlessness and/or a drop in blood pressure and fainting. If you present any of the following or a combination of nausea, vomiting, diarrhoea or abdominal pain, talk to your doctor, pharmacist, or nurse prior to taking the vaccine. Vaccination should be postponed until after recovery because protection against cholera may be diminished.
1
Not everyone taking this vaccine will be fully protected against cholera. It is important to continue to follow hygiene advice and take special care with food and water in cholera-affected areas. This vaccine may be less effective if you have HIV. Bacteria from the vaccine may be present in your stool for at least 7 days after you take the vaccine. To prevent any contamination, wash your hands thoroughly after visiting the toilet, changing nappies and before preparing food for at least 14 days after you take this vaccine. Children and adolescents Do not give this vaccine to children younger than 2 years of age because it is not known how well it works in this age group. Other medicines and Vaxchora Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines or vaccines. This includes medicines obtained without a prescription, including herbal medicines. This is because this vaccine can affect the way some other medicines and vaccines work. In particular tell your doctor, pharmacist or nurse if you are taking: • antibiotics – this vaccine may not work if you take it while you are also taking antibiotics. Take this vaccine no earlier than 14 days after the last dose of an antibiotic. Avoid antibiotics for 10 days after taking this vaccine. • chloroquine for malaria prevention – this vaccine may not work if you take it while you are also taking chloroquine. Take this vaccine at least 10 days before starting chloroquine or 14 days after taking chloroquine. • the typhoid vaccine Ty21a – this vaccine may not work if it is taken at the same time as Ty21a. You should take this vaccine at least 2 hours before or after taking Ty21a. If any of the above apply to you, talk to your doctor, pharmacist or nurse before taking this vaccine. Vaxchora with food and drink You must not eat or drink for 60 minutes before and after taking this vaccine as this may reduce the vaccine's effectiveness. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines Vaxchora vaccine has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section 4 "Possible side effects" may temporarily affect the ability to drive or use machines. Do not drive or use machines if you are feeling unwell after vaccination. Vaxchora contains lactose, sucrose, and sodium If you have been told by your doctor that you have an intolerance to some sugars contact your doctor before taking this medicinal product. This vaccine contains 863 mg of sodium (the main component of cooking/table salt) per dose. This is equivalent to 43% of the recommended daily dietary intake of sodium for an adult. Please take this into account if you are on a controlled sodium diet.
3.
Vaxchora
Always take this vaccine exactly as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure. 2
The recommended dose is the contents of both sachets in the carton. However for children 2 to less than 6 years old take note of Step 8 in the instructions on how to prepare the vaccine, shown below. Protection against cholera is established within 10 days after taking Vaxchora. Your doctor, pharmacist or nurse will tell you how soon before travelling to take the vaccine. Instructions: PREPARE THIS VACCINE EXACTLY AS DESCRIBED IN THIS LEAFLET Please read the following before you begin: Vaxchora may not work if the following occurs: • Incorrect storage; the vaccine must be stored in the refrigerator (2°C – 8°C). • Using the incorrect amount of water; 100 mL must be used. • Using the incorrect type of water; bottled water that is cold or room temperature and noncarbonated or carbonated must be used. • Mixing the sachets in the wrong order; sachet 1 must be added to the water first. If the sachets are mixed in the wrong order you must discard the vaccine and request a replacement dose. • Eating or drinking; must be avoided 60 minutes before and after taking the vaccine, eating or drinking can reduce the effectiveness of the vaccine. Do not touch your eyes when you prepare the vaccine to avoid contamination. If any powder or liquid gets spilt, clean the surface with hot water and soap or an antibacterial disinfectant. If there is a significant spill (more than a few drops of liquid or grains of powder), dispose of the vaccine and get a new one from your doctor or pharmacist; DO NOT take the remaining medication. Step 1 Gather materials: • Clean cup • Utensil to stir • Bottled water (non-carbonated or carbonated, cold or room temperature, 25°C or less) • Item to measure 100 mL of bottled water (e.g. measuring jug) • Scissors Step 2 Remove the vaccine from the refrigerator.
3
Step 3
Locate the two sachets: the sachets are labelled 1 and 2. Sachet 1 contains "Vaxchora Buffer" and is black and white. Sachet 2 contains "Vaxchora Active ingredient" and is blue and white. If a sachet is not intact, do not use either sachet and contact your doctor, pharmacist or nurse about acquiring a replacement dose; using a sachet that is not intact can reduce the effectiveness of the vaccine. Measure 100 mL of bottled cold or room temperature non-carbonated or carbonated water and pour into a clean cup.
Step 4
Using bottled water is necessary for the vaccine to be effective – using non-bottled (e.g. tap water) may render the vaccine ineffective. Step 5
Use scissors to cut off the top of sachet 1. Do not put your fingers into the sachet. Wash your hands if you touch the sachet contents, in order to reduce the chance of contamination.
Step 6
Empty the contents of sachet 1 into the water in the cup. It will fizz.
Step 7
Stir until the powder completely dissolves.
Step 8
For children age 2 to <6 years only: Pour away and discard half of the buffer solution. (Note: For children over 6 years and adults this step is NOT required)
4
Step 9
Use scissors to cut off the top of sachet 2. Do not put your fingers into the sachet. Wash your hands if you touch the sachet contents, in order to reduce the chance of contamination.
Step 10
Empty the contents of sachet 2 into the cup.
Step 11
Stir for at least 30 seconds. The powder from sachet 2 may not dissolve completely. It will form a slightly cloudy mixture with some white particles. If desired, after stirring in sachet 2 for at least 30 seconds, stevia sweetener (no more than 1 gram or 1⁄4 teaspoon) or sugar (sucrose, not more than 4 grams or 1 teaspoon) may be added, and then stirred into the suspension. DO NOT add other sweeteners as this may reduce the effectiveness of the vaccine. Drink the full contents of the cup within 15 minutes of preparing it. Some residue may remain in the cup and must be discarded. If you or your child take less than half of the dose, contact your doctor, pharmacist, or nurse right away about the need for a repeat dose.
Step 12
Step 13
Dispose of the empty sachets according to local biosafety guidelines. Ask your doctor, pharmacist or nurse how to throw away medicine waste material.
5
Step 14
If a spill occurs while stirring or drinking the medication, or there is any residue (powder or liquid left behind from a stirring utensil, cup, or other object) on the mixing surface, clean up spilled material or residue preferably with a disposable paper towel/cloth using hot water and soap or antibacterial disinfectant. Discard the paper towel together with the sachets (see above). Wash the cup and spoon or stirrer with soap and hot water.
Step 15
Step 16
Wash your hands thoroughly with soap and hot water to prevent contamination.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
4.
Like all vaccines, this vaccine can cause side effects, although not everybody gets them. Contact a doctor immediately if you get the following serious side effects: • serious allergic reactions causing swelling of the face or throat, hives, itchy rash, breathlessness and/or a drop in blood pressure and fainting. Other side effects: Very common side effects (may affect more than 1 in 10 people) • tiredness, • headache, • stomach pains, • feeling or being sick, • decreased appetite. Common side effects (may affect up to 1 in 10 people) • diarrhoea. Uncommon side effects (may affect up to 1 in 100 people) • fever, 6
• • • • • • • • • •
joint pain, dizziness, bloating (abdominal distension), rash, dry mouth, constipation, flatulence, burping, indigestion, abnormal feaces.
Rare side effects (may affect up to 1 in 1 000 people): • chills. Additional side effects in children and adolescents Based on clinical trials the type of adverse reactions in children are expected to be similar to those in adults. Some adverse reactions were more common in children than adults such as tiredness, stomach pain, vomiting, decreased appetite and fever. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine. 5.
Vaxchora
Keep this vaccine out of the sight and reach of children. Do not use this vaccine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month. Store in a refrigerator (2°C – 8°C). Store in the original package in order to protect from light and moisture. The vaccine in the original package is stable for up to 12 hours at 25°C. At the end of this period the vaccine should be used immediately or discarded. Avoid exposing Vaxchora to temperatures above 25°C. Do not use this vaccine if you notice the sachets are damaged and contact your doctor, pharmacist, or nurse for a replacement dose. This medicine contains genetically-modified organisms. Local biosafety guidelines should be followed for unused medicine or waste material. Ask your doctor, pharmacist or nurse how to throw away medicines you no longer use or waste material.
6.
What Vaxchora contains – Each dose contains 4×108 to 2×109 viable cells of Vibrio cholerae strain CVD 103-HgR1. – The other ingredients are sucrose, hydrolysed casein, ascorbic acid, lactose, sodium bicarbonate, and sodium carbonate (see Section 2. Vaxchora contains lactose, sucrose and sodium). – This vaccine contains genetically modified organisms (GMOs). 1
Produced by recombinant DNA technology.
7
What Vaxchora looks like and contents of the pack One dose of Vaxchora effervescent powder and powder for oral suspension is provided in a carton containing two sachets. One sachet contains white-to-off-white buffer sodium hydrogen carbonate effervescent powder. The other sachet contains white-to-beige active ingredient vaccine powder for oral suspension. Marketing Authorisation Holder Bavarian Nordic A/S, Philip Heymans Alle 3, DK-2900 Hellerup, Denmark Manufacturer Smiro Qualitas Limited 4 Flatford Road Haverhill, CB9 7WW United Kingdom This leaflet was last revised in 05/2026. Other sources of information Detailed information on this medicine is available on the MHRA website: http://www.mhra.gov.uk.
8
The active substance in Vaxchora, cholera vaccine (recombinant, live, oral) is vibrio cholerae live attenuated.
This leaflet reproduces the patient information leaflet approved for Vaxchora, cholera vaccine (recombinant, live, oral), as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Vaxchora is indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children aged 2 years and older.
This vaccine should be used in accordance with official recommendations.
Posology
Adults and children aged 2 years and older
A single oral dose should be administered at least 10 days prior to potential exposure to Vibrio cholerae O1.
Consumption of less than a half dose may result in decreased protection. If less than half the dose is consumed, consideration may be given to repeating a full dose of Vaxchora within 72 hours.
Revaccination
No data are available on revaccination interval.
Paediatric population
The safety and efficacy of Vaxchora in children less than 2 years has not been established. No data are available.
Method of administration
Oral use.
For instructions on reconstitution of Vaxchora prior to administration, see section 6.6.
Eating and drinking should be avoided 60 minutes before and after oral ingestion of this vaccine.
The reconstituted vaccine forms a slightly cloudy suspension that may contain some white particulates. After reconstitution, the suspension should be drunk within 15 minutes. The recipient should drink the full contents of the cup at once.
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
Individuals with congenital immune deficiency or receiving immunosuppressive treatment.
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Factors affecting protection
Vaxchora confers protection specific to Vibrio cholerae serogroup O1. Immunisation does not protect against Vibrio cholerae O139 or other species of Vibrio.
This vaccine does not provide 100% protection. Vaccinees should adhere to hygiene advice and exercise caution regarding food and water consumed in cholera-affected areas.
No data are available in persons living in cholera-affected areas or in individuals with pre-existing immunity to cholera.
The protection afforded by this vaccine may be reduced in HIV-infected individuals.
Potential risk to contacts
Vaxchora shedding in the stools was studied for 7 days post-vaccination, and was observed in 11.3% of vaccine recipients. The duration of shedding of the vaccine strain is unknown. There is a potential for transmission of the vaccine strain to non-vaccinated close contacts (e.g., household contacts).
Concomitant administration with antibacterial agents and/or chloroquine
Concomitant administration with antibacterial agents and/or chloroquine should be avoided because protection against cholera may be diminished (see section 4.5).
Gastrointestinal Disease
In individuals with acute gastroenteritis, vaccination should be postponed until after recovery, because protection against cholera may be diminished. The degree of protection and the effects of vaccination in individuals with chronic gastrointestinal disease are unknown.
Limitations of the clinical data
Clinical trials were conducted in individuals age 2 to 64 years old. Efficacy was demonstrated in a human cholera challenge at 10 days or 3 months post-vaccination in adults age 18-45 years and immunobridging to other populations based on the rate of seroconversion. Immunogenicity data are available for 24 months post-vaccination (see section 5.1). There are no immunogenicity or efficacy data in individuals over 64 years of age.
Excipients
This vaccine contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
This vaccine contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
This vaccine contains 863 mg of sodium per dose, equivalent to 43% of the WHO recommended maximum daily intake of 2 g of sodium for a healthy adult.
No interaction studies have been performed with Vaxchora, however data and clinical experience from other vaccines can be applicable to this vaccine.
Oral typhoid vaccine
There should be an interval of 2 hours between the administration of this vaccine and of typhoid vaccine Ty21a (gastro-resistant capsules) as the buffer administered with this vaccine may affect the transit of the capsules through the gastrointestinal tract.
Antibiotics
Concomitant administration of this vaccine with systemic antibiotics active against Vibrio cholerae should be avoided since these agents may prevent a sufficient degree of replication to occur in order to induce a protective immune response. This vaccine should not be administered to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination. Oral or parenteral antibiotics should be avoided for 10 days following vaccination with this vaccine.
Antimalarial prophylaxis
Data from the study of a previous CVD 103-HgR-based vaccine indicate that immune responses to Vaxchora and protection against cholera may be diminished when this vaccine is administered concomitantly with chloroquine. Administer this vaccine at least 10 days before beginning antimalarial prophylaxis with chloroquine. There are no data regarding concomitant use of this vaccine with other anti-malarial drugs.
Food and drink
The vaccine is acid-labile and is administered with a buffer. Eating and drinking should be avoided for 60 minutes before and after taking this vaccine as this may interfere with the protective effect of the buffer.
Pregnancy
There are limited data from the use of Vaxchora in pregnant women.
Animal studies are insufficient with respect to reproductive toxicity (see section 5.3).
This vaccine should be used during pregnancy only if the potential benefits to the mother outweigh the potential risks, including those to the foetus.
Breast-feeding
It is unknown whether Vaxchora is excreted in human milk. A risk to the breastfed child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to abstain from using this vaccine taking into account the benefit of breast feeding for the child and the benefit of the vaccine for the woman.
Fertility
No human or animal data on the effect of Vaxchora on fertility are available.
Vaxchora has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under Section 4.8 (e.g., fatigue, dizziness) may temporarily affect the ability to drive or use machines.
Summary of safety profile
The most frequent reported adverse reactions following Vaxchora administration are fatigue (30.2%), headache (28.3%), abdominal pain (18.4%), nausea/vomiting (17.9%), and decreased appetite (15.7%).
Tabulated summary of adverse reactions
The adverse reaction frequency classification used is as follows: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10,000 to <1/1 000); very rare (<1/10 000), not known (cannot be estimated from the available data).
Adverse Reactions
Frequency
Metabolism and nutrition disorders
Decreased appetite
Very common
Nervous system disorders
Headache
Very common
Dizziness
Uncommon
Gastrointestinal disorders
Abdominal pain, nausea/vomiting
Very common
Diarrhoea
Common
Flatulence, constipation, abdominal distension, dyspepsia, abnormal faeces, dry mouth, eructation
Uncommon
Skin and subcutaneous tissue disorders
Rash
Uncommon
Musculoskeletal and connective tissue disorders
Arthralgia
Uncommon
Chills
Rare
General disorders and administration site conditions
Fatigue
Very common
Pyrexia
Uncommon
Paediatric population
A clinical trial was conducted in 550 children age 2 to <18 years. Based on the results of this trial the type of adverse reactions in children are expected to be similar to those in adults. Some adverse reactions were more common in children than adults, including fatigue (35.7% vs 30.2%), abdominal pain (27.8% vs 18.4%), vomiting (3.8% vs 0.2%), decreased appetite (21.4% vs 15.7%) and pyrexia (2.4% vs 0.8%).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
There have been reports of multiple doses of Vaxchora being administered several weeks apart. The adverse reactions reported were comparable to those seen after the recommended dose.
Ask anything about Vaxchora, cholera vaccine (recombinant, live, oral). The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.